Solazyme Receives FDA GRAS No Questions Letter for High Oleic Algae Oil
Solazyme, Inc. (NASDAQ:SZYM) , a renewable oil and ingredients company, is pleased to announce that the US Food and Drug Administration (FDA) has issued a favorable response to Solazyme’s notification which concludes that high-oleic algae oil is Generally Recognized as Safe (GRAS) as an ingredient in food products under the intended conditions of use.
This No Questions letter will further pave the way for mainstream adoption of superior quality oleic algae oil with unprecedented functional, performance and nutritional benefits, enabling the creation of new products that meet consumer demand for healthy, sustainable ingredients.
Solazyme’s portfolio of high oleic algae oils are unique in that they can offer an unprecedented amount of healthy monounsaturated fat (omega-9s), and 0g trans fat with exceptional stability and low levels of saturated fat. They have a very light color and neutral flavor allowing the flavor of foods to come through in recipes. Solazyme’s High Stability High Oleic algae oil received the prestigious 2014 Innovation Award from the Institute of Food Technologists.
“We’re committed to delivering innovative ingredients that are better for both people and the planet. Our algae oils offer more favorable fat profiles than olive oil, and higher smoke points than canola, helping customers respond to the growing demand for great tasting and nutritious food,” said Mark Brooks, SVP, Solazyme Food Ingredients.
Solazyme has also received FDA No Questions letters for the whole food ingredient products currently offered within the AlgaViaTM portfolio, including Whole Algal Protein and Whole Algal Flour.
Whole Algal Protein is a vegan-friendly, gluten-free product that contains a rich collection of protein with fiber, lipids and micronutrients such as lutein and zeaxanthin. With a protein that is protected by a natural cell wall, this ingredient enables fortification in challenging applications such as low pH beverages, dressings and crackers.
Whole Algal Flour is a trans-fat- and cholesterol-free lipid powder that enables the creation of healthier products with satisfying taste and texture. This new fat source enables the reduction or replacement of dairy fats, oil and egg yolks.
About Solazyme, Inc.
Solazyme, Inc. (Nasdaq:SZYM) is a leading microalgae innovator that delivers first-of-a-kind, high-performance oils and ingredients that are better for people and better for the planet. Starting with microalgae, the world’s original oil producer, Solazyme creates new, sustainable, high-performance products. These include renewable oils and powerhouse ingredients that serve as the foundation for healthier foods; better home, personal care and industrial products; and more sustainable fuels. Headquartered in South San Francisco, Solazyme’s mission is to solve some of the world’s biggest problems with one of its smallest and most ancient life forms: microalgae.
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Solazyme, including statements that involve risks and uncertainties concerning: its commercialization and production plans; meeting commercialization and technology targets; market acceptance of its products; and Solazyme’s ability to maintain its relationships with its partners. When used in this press release, the words “will”, “can”, “anticipate”, “intends” and other similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Solazyme, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this press release due to a number of risks and uncertainties. Potential risks and uncertainties include, among others: Solazyme’s limited operating history; its limited history in commercializing products; implementation risk in deploying new technologies; its limited experience in constructing, ramping up and operating commercial manufacturing facilities; its ability to sell its products at a profit; delays related to start-up and ramp-up of production facilities; its ability to manage operational costs at production facilities; its ability to enter into and maintain strategic collaborations; successful product trials by its customers and market acceptance of its products by end-users; its ability to obtain requisite regulatory approvals; and its access, on favorable terms, to any required financing. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Solazyme.
In addition, please refer to the documents that Solazyme, Inc. files with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q, as updated from time to time, for a discussion of these and other risks. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. Solazyme is not under any duty to update any of the information in this press release.
Sorry. No data so far.